A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma Herodotus - observacional - Institut d'Investigacions Biomèdiques August Pi i Sunyer

ID: GETNE T1812 DUTHY

Fecha inicio

27-05-2025

Fecha fin

N/A

Basté Rotllan, NeusPrincipal investigator

Projects in Health Area

Project of Innovation Health

A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma Herodotus - observacional

Researchers: Basté Rotllan, Neus

Hospital Clinic de Barcelona. Hospital Clinic de Barcelona - ICMHO (Sanitary institutions)